Psilocybin-Assisted Alcohol Use Disorder Outpatient Program A structured addiction treatment service combining two supervised psilocybin sessions with motivational enhancement and cognitive-behavioral therapy, targeting AUD patients where the clinical trial cut heavy drinking days from 23.6% to 9.7% over 32 weeks.
Why it helps: As the largest nonprofit addiction treatment network in the US, Hazelden Betty Ford could integrate this protocol into its existing evidence-based residential and outpatient programs, substantially improving outcomes for the AUD patients who cycle through repeated treatment episodes.